Human embryonic kidney 293T cells , and DU145 cells, were grown in RPMI 1604 supplemented with 10% fetal bovine serum and 1X penicillin/streptomycin (all from Life Technologies, Grand Island, NY) in a 100% humidified 5% CO2 incubator at 37°C.
Lenti TGFBRII-gRNA/Cas9 constructs, 293T transfection, and transduction of DU145
The targeting of single guide RNA (gRNA), designed to target N-terminal of human TGFBRII gene to increase the gRNA efficiency, using Michael Boutros lab's Target Finder (E-CRISP; http://www.e-crisp. org/E-CRISP/designcrispr.html), was introduced into a lentiviral vector lentiCRISPR, a gift from Dr. Feng Zhang (Addgene plasmid # 49535; Cambridge, MA), delivering Cas9, a gRNA and a puromycin selection marker into target cells. 293T cells, seeded in 100mm tissue culture dishes (Invitrogen Corporation, Carlsbad, CA) were transfected with 4 µg each of lenti TGFBRII-gRNA/Cas9, psPAX2 and pMD2.G (both are gifts from Didier Trono; Addgene plasmid # 12260 and # 12259, respectively), using Lipofectamine 2000 (Invitrogen Corporation), including controls without plasmid and/or Lipofectamine 2000, per the manufacturer's instructions. Fresh medium was replaced the following day and, after an additional 24 hours, the supernatant was harvested by centrifugation and filtered through 0.45-µm filters.
DU145 cells in 6-well tissue culture plates (Invitrogen Corporation) were infected with the filtered supernatant of 293T, together with 8 µg/ml of polybrene (Sigma-Aldrich Co. LLC., St Louis, MO), followed by medium renewal supplemented with 0.5 µg/ml of puromycin (Life Technologies) the following day, and then after an additional 24 hours, cells were expanded and seeded into 100mm tissue culture dishes (Invitrogen Corporation). Controls included the supernatant of 293T without plasmid and/or Lipofectamine 2000. About 2 weeks later, single cell clones were picked up individually and placed into 24-well tissue culture plates (Invitrogen Corporation), and later into 6-well tissue culture plates (Invitrogen Corporation). Genomic DNA (gDNA) was extracted from cells, subjected to PCR amplification using PyroMark PCR kit (QIAGEN, Valencia, CA), and subsequently purified products were sequenced to confirm gene editing.
Validation of the prognostic effect of TGFBRII mRNA in prostate cancer dataset
We used an online biomarker validation tool and database SurvExpress ( http://bioinformatica.mty.itesm. mx:8080/Biomatec/SurvivaX.jsp) [1] to perform survival analysis, providing Kaplan-Meier log rank analysis and risk assessment using TGFBRII gene list as input to a Cox proportional-hazards regression. The largest normalized dataset (GSE10645-GPL5858) with 596 samples that included overall survival times and survival after radical retropubic prostatectomy (Survival_After_RRP) was used. For replicated genes, we selected the average expressed probe and maximize risk groups. Overall survival times, relapse-free survival and risk analysis were performed in which a predicted risk for a prostate cancer patient genetic profile was determined. The subjects were then partitioned into low risk and high risk groups [1] .
Computational prediction of the stability of mutation TGFBRII
We used I-Mutant2.0 (http://folding.biofold.org/imutant/i-mutant2.0.html) [2] to predict the potential stability change of TGFBRII upon amino acid substitution (T23I), using protein structure as input without changing any default parameters.
Prostate cancer patient blood samples and CTCs analysis
Eight ml of blood samples from PrCa patients were used to isolate CTCs for AFM and/or immunofluorescence analyses as reported previously [3] . We calculated nanomechanical parameters including elasticity, cell deformation and adhesion, as described [3] . Following staining of the same cells with specific fluorescently labeled antibodies we counted EMT-and non-EMTCTCs as well as large innate immunity cells identified as macrophages, copurifying with CTCs. We identified as M1-like or intermediate cells with high levels of CD14 and/or CD80 antigens, and as M2-like cells with low or
